Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them

Abstract

Solutions which contain L-carnitine and alkanoyl L-carnitine are useful for stabilizing blood for transfusions.

I claim: 
     
       1. A method for stabilizing blood for transfusion, comprising mixing blood with a solution, said solution comprising L-carnitine, alkanoyl L-carnitine, or a pharmaceutically acceptable salt thereof, wherein said pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, orotate, aspartic acid, acid citrate, acid phosphate, fumarate, acid fumarate, maleate, acid maleate, acid oxalate, acid sulfate, glucoses phosphate, tartrate, and acid tartrate, and wherein said solution comprises 0.5-10.0 mM/L of said L-carnitine, said alkanoyl L-carnitine, or said pharmaceutically acceptable salt thereof. 
     
     
       2. The method of claim 1, wherein said alkanoyl L-carnitine is selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, isobutyryl L-carnitine, valeryl L-carnitine, and isovaleryl L-carnitine. 
     
     
       3. The method of claim 1, wherein said solution comprises:   ______________________________________
Glucose               80-120 mM/L
Mannitol              40-60 mM/L
K.sub.2 HPO.sub.4     24-28 mM/L
KH.sub.2 PO.sub.4     12-16 mM/L
Potassium citrate     15-20 mM/L
L-carnitine, internal salt
                      4-6 mM/L.
______________________________________
     
     
     
       4. The method of claim 1, wherein said solution comprises 4-6 mM/L of said L-carnitine, said alkanoyl L-carnitine, or said pharmaceutically acceptable salt. 
     
     
       5. The method of claim 1, wherein said solution is mixed with said blood in a ratio to obtain a ratio of volume of solution to volume of erythrocytes of about 1:1. 
     
     
       6. A transfusion bag which comprises: (a) a sample of whole blood;   (b) a preservative-anticoagulant solution; and   (c) 4-6 mM/L of L-carnitine, alkanoyl L-carnitine or a pharmaceutically acceptable salt thereof, wherein said pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, orotate, aspartic acid, acid citrate, acid phosphate, fumarate, acid fumarate, maleate, acid maleate, acid oxalate, acid sulfate, glucoses phosphate, tartrate, and acid tartrate.   
     
     
       7. The transfusion bag of claim 6, wherein said preservative-anticoagulant solution is selected from ACD, CPD and CPDA-1. 
     
     
       8. The transfusion bag of claim 6, wherein said alkanoyl L-carnitine is selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, isobutyryl L-carnitine, valeryl L-carnitine, and isovaleryl L-carnitine. .Iadd. 
     
     
       9.  A method for stabilizing a composition for transfusion comprising erythrocytes, said method comprising mixing said composition with a solution, said solution comprising L-carnitine, alkanoyl L-carnitine, or a pharmaceutically acceptable salt thereof, wherein said pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, orotate, aspartic acid, acid citrate, acid phosphate, fumarate, acid fumarate, maleate, acid maleate, acid oxalate, acid sulfate, glucose phosphate, tartrate and acid tartrate, and wherein said solution comprises 0.5-10.0 mM/L of said L-carnitine, said alkanoyl L-carnitine, or said pharmaceutically acceptable salt thereof. .Iaddend..Iadd.10. A transfusion bag which comprises: (a) a composition comprising erythrocytes;   (b) a preservative-anticoagulant solution; and   (c) 4-6 mM/L of L-carnitine, alkanoyl L-carnitine or pharmaceutically acceptable salt thereof, wherein said pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, orotate, aspartic acid, acid citrate, acid phosphate, fumarate, acid fumarate, maleate, acid maleate, acid oxalate, acid sulfate, glucose phosphate, tartrate and acid tartrate, and wherein said solution comprises 0.5-10.0 mM/L of said L-carnitine, said alkanoyl L-carnitine, or said pharmaceutically acceptable salt thereof. .Iaddend..Iadd.11. The method of claim 9, wherein said alkanoyl L-carnitine is selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, isobutyryl L-carnitine, valeryl L-carnitine, and isovaleryl L-carnitine.   
     
     
        .Iaddend..Iadd.12.  The method of claim 9, wherein said solution comprises:   ______________________________________
Glucose               80-120 mM/L
Mannitol              40-60 mM/L
K.sub.2 HPO.sub.4     24-28 mM/L
KH.sub.2 PO.sub.4     12-16 mM/L
Potassium citrate     15-20 mM/L
L-carnitine, internal salt
                      4-6 mM/L.
______________________________________
     .Iaddend..Iadd.13. The method of claim 9, wherein said solution comprises 4-6 mM/L of said L-carnitine, said alkanoyl L-carnitine, or said pharmaceutically acceptable salt. .Iaddend..Iadd.14. The transfusion bag of claim 10, wherein said preservative-anticoagulant solution is selected from ACD, CPD and CPDA-1. .Iaddend..Iadd.15. The transfusion bag of claim 10, wherein said alkanoyl L-carnitine is selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, isobutyryl L-carnitine, valeryl L-carnitine, and isovaleryl L-carnitine. .Iaddend.